Emergent BioSolutions (EBS) Registration Filing summary

Company overview and business model

• Operates as a global life sciences company focused on preparedness and response solutions for public health threats, including chemical, biological, radiological, nuclear, infectious diseases, and acute care.

• Product portfolio includes 11 products such as vaccines, therapeutics, and drug-device combinations, with significant revenue from NARCAN® and KLOXXADO® nasal sprays.

• Business is structured into Commercial Products, MCM (Medical Countermeasure) Products, and Bioservices (CDMO), with Commercial and MCM Products as reportable segments.

Financial performance and metrics

• As of July 30, 2025, 53,351,099 shares of common stock were outstanding, held by 46 stockholders.

• Common stock last traded at $6.03 per share on August 6, 2025, on the NYSE.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including capital expenditures, working capital, product development, administrative expenses, debt repayment, or acquisitions.

• Pending use, proceeds may be invested in short-term, investment-grade, interest-bearing instruments.